Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Registration Number
- NCT05803941
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
- Detailed Description
This is a global, prospective, multi-center, long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
There will be no study treatment administered to participants in this study. Participants will have visits every 6-8 months for monitoring of selected AEs and laboratory parameters. The study periods include a Baseline and Follow-up Period (up to 10 years after first dose of AAA617 in parent treatment study).
Participants should enroll into the LTFU study after parent treatment study requirements are fulfilled (refer to the parent treatment study protocol for requirements, including any additional requirements after participant enters this LTFU safety study).
The schedule of activities for this LTFU study is designed to start from date of informed consent for this LTFU study. Participants should be followed every 6 to 8 months for up to a total of 10 years starting from first dose of AAA617 in the parent treatment study. Participants entering the LTFU study will have already completed a variable portion of the required 10-year follow-up within the parent treatment study. The specific number of visits required in this LTFU study will depend upon the time of enrollment into this LTFU study following the first dose of AAA617 in the parent treatment study.
The total number of participants to be enrolled and the duration of this LTFU study will depend upon the total number treated in the parent treatment studies and their duration.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 700
- Signed informed consent must be obtained prior to participation in the study
- Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.
- Inability to complete the needed investigational examinations due to any reason.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single arm AAA617 Participants will be followed until death, lost to follow-up, or up to 10 years from first dose of AAA617, whichever occurs first. There will be no study treatment administered to participants while participating in this study.
- Primary Outcome Measures
Name Time Method Number and percentage of participants with selected Adverse Events (AEs) and Serious Adverse Events (SAEs) every visit up to 10 years after 1st dose of AAA617 received in parent treatment study Selected adverse events (AEs) include xerostomia, xerophtalmia, myelosupression, renal toxicity and second primary malignancy and their complication. Only SAEs considered causally related to previous treatment with AAA617 will be considered.
- Secondary Outcome Measures
Name Time Method Number and percentage of participants who have died every visit up to 10 years after 1st dose of AAA617 received in parent treatment study The number and percentage of participants who die during the long-term follow-up will be summarized.
Absorbed radiation dose in kidney or other selected organs and number of AEs every visit up to 10 years after 1st dose of AAA617 received in parent treatment study Correlation between absorbed radiation dose in kidney or selected organs and safety of AAA617 for participants with dosimetry estimates collected in the parent treatment study.
Trial Locations
- Locations (25)
Mayo Clinic Arizona
🇺🇸Scottsdale, Arizona, United States
St. Joseph Hospital
🇺🇸Orange, California, United States
Providence Saint Johns Health Ctr
🇺🇸Santa Monica, California, United States
University of Colorado
🇺🇸Aurora, Colorado, United States
Hartford Hospital
🇺🇸Hartford, Connecticut, United States
VA Medical Center
🇺🇸Washington, District of Columbia, United States
Mayo Clinic Jacksonville
🇺🇸Jacksonville, Florida, United States
University Cancer and Blood Center LLC
🇺🇸Athens, Georgia, United States
Parkview Research Center
🇺🇸Fort Wayne, Indiana, United States
Tulane Cancer Center
🇺🇸New Orleans, Louisiana, United States
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
Corewell Health William Beaum Hosp
🇺🇸Royal Oak, Michigan, United States
Mayo Clinic Rochester
🇺🇸Rochester, Minnesota, United States
University of Mississippi Med Ctr
🇺🇸Jackson, Mississippi, United States
Wash U School of Medicine
🇺🇸Saint Louis, Missouri, United States
Urology Cancer Center PC
🇺🇸Omaha, Nebraska, United States
Nebraska Cancer Specialists
🇺🇸Omaha, Nebraska, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Univ of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Univ of Texas Southwest Med Center
🇺🇸Dallas, Texas, United States
UT Health Science Center
🇺🇸Houston, Texas, United States
Onco Hemato Asso of SE Virginia
🇺🇸Roanoke, Virginia, United States
Novartis Investigative Site
🇬🇧Middlesbrough, United Kingdom